Modeling and predicting clinical efficacy for drugs targeting the tumor milieu (Q38025261)

27 August 2017

Modeling and predicting clinical efficacy for drugs targeting the tumor milieu (English)

1 reference

27 August 2017

Mallika Singh

1

1 reference

PubMed ID

22781694

27 August 2017

Napoleone Ferrara

series ordinal

2

1 reference

27 August 2017

10 July 2012

1 reference

27 August 2017

1 reference

27 August 2017

30

1 reference

27 August 2017

7

1 reference

27 August 2017

648-657

1 reference

https://scigraph.springernature.com/pub.10.1038/nbt.2286

27 August 2017

0 references

cites work

Development trends for new cancer therapeutics and vaccines.

1 reference

Tumor-host interactions: a far-reaching relationship

21 January 2018

1 reference

Hallmarks of cancer: interactions with the tumor stroma.

21 January 2018

1 reference

Angiogenesis as a therapeutic target

21 January 2018

1 reference

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade

21 January 2018

1 reference

Cancer associated fibroblasts (CAFs) in tumor microenvironment

21 January 2018

1 reference

Genetically engineered models have advantages over xenografts for preclinical studies

21 January 2018

1 reference

Contributions of human tumor xenografts to anticancer drug development

21 January 2018

1 reference

The mighty mouse: genetically engineered mouse models in cancer drug development

21 January 2018

1 reference

Using genetically engineered mouse models of cancer to aid drug development: an industry perspective

21 January 2018

1 reference

Towards systematic functional characterization of cancer genomes

21 January 2018

1 reference

Technologically advanced cancer modeling in mice

21 January 2018

1 reference

Unraveling the genetics of cancer: genome sequencing and beyond

21 January 2018

1 reference

Non-germline genetically engineered mouse models for translational cancer research

21 January 2018

1 reference

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

21 January 2018

1 reference

Mouse models of advanced spontaneous metastasis for experimental therapeutics

21 January 2018

1 reference

Does tumour dormancy offer a therapeutic target?

21 January 2018

1 reference

Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development

21 January 2018

1 reference

Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors

21 January 2018

1 reference

Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent Hedgehog pathway activation

21 January 2018

1 reference

Prediction of exposure-response relationships to support first-in-human study design

21 January 2018

1 reference

Predictive toxicology approaches for small molecule oncology drugs

21 January 2018

1 reference

Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF.

21 January 2018

1 reference

Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies

21 January 2018

1 reference

Precompetitive preclinical ADME/Tox data: set it free on the web to facilitate computational model building and assist drug development

21 January 2018

1 reference

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

21 January 2018

1 reference

Finding the tumor copycat: approximating a human cancer

21 January 2018

1 reference

Guidelines for the welfare and use of animals in cancer research

21 January 2018

1 reference

Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies.

21 January 2018

1 reference

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

21 January 2018

1 reference

Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction?

21 January 2018

1 reference

Antiangiogenic agents and targets: A perspective.

21 January 2018

1 reference

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

21 January 2018

1 reference

Induction of angiogenesis during the transition from hyperplasia to neoplasia

21 January 2018

1 reference

Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment

21 January 2018

1 reference

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

21 January 2018

1 reference

Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy.

21 January 2018

1 reference

Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer

21 January 2018

1 reference

Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action

21 January 2018

1 reference

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.

21 January 2018

1 reference

Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization

21 January 2018

1 reference

Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.

21 January 2018

1 reference

Incorporation of bevacizumab in the primary treatment of ovarian cancer

21 January 2018

1 reference

A phase 3 trial of bevacizumab in ovarian cancer

21 January 2018

1 reference

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

21 January 2018

1 reference

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

21 January 2018

1 reference

Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies

21 January 2018

1 reference

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

Pericytes limit tumor cell metastasis

21 January 2018

1 reference

Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway

21 January 2018

1 reference

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

21 January 2018

1 reference

Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption

21 January 2018

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

Cancer immunotherapy comes of age

21 January 2018

1 reference

Cancer and immune response: old and new evidence for future challenges.

21 January 2018

1 reference

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4

21 January 2018

1 reference

Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4

21 January 2018

1 reference

Immunostimulatory monoclonal antibodies for cancer therapy

21 January 2018

1 reference

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

21 January 2018

1 reference

Enhancement of antitumor immunity by CTLA-4 blockade

21 January 2018

1 reference

Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accomp

21 January 2018

1 reference

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

21 January 2018

1 reference

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

21 January 2018

1 reference

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

21 January 2018

1 reference

Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy

21 January 2018

1 reference

Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy

21 January 2018

1 reference

Combining immunotherapy and targeted therapies in cancer treatment

21 January 2018

1 reference

Tumor stroma and regulation of cancer development

21 January 2018

1 reference

PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment

21 January 2018

1 reference

DNA damage-mediated induction of a chemoresistant niche

21 January 2018

1 reference

FcRgamma activation regulates inflammation-associated squamous carcinogenesis.

21 January 2018

1 reference

Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis

21 January 2018

1 reference

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells.

21 January 2018

1 reference

Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner.

21 January 2018

1 reference

Chemotherapeutic resistance: surviving stressful situations

21 January 2018

1 reference

In vivo/ex vivo and in situ assays used in cancer research: a brief review

21 January 2018

1 reference

Modeling therapy resistance in genetically engineered mouse cancer models

21 January 2018

1 reference

Mouse models of human AML accurately predict chemotherapy response

21 January 2018

1 reference

Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer

21 January 2018

1 reference

Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma

21 January 2018

1 reference

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

21 January 2018

1 reference

Bv8 regulates myeloid-cell-dependent tumour angiogenesis

21 January 2018

1 reference

Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition

21 January 2018

1 reference

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

Drug development: Raise standards for preclinical cancer research

21 January 2018

1 reference

Translational research: The American way.

21 January 2018

1 reference

Envisioning the future of early anticancer drug development.

21 January 2018

1 reference

Lung cancer signatures in plasma based on proteome profiling of mouse tumor models

21 January 2018

1 reference

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

21 January 2018

1 reference

Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer

21 January 2018

1 reference

A rapid and scalable system for studying gene function in mice using conditional RNA interference

21 January 2018

1 reference

Towards patient-based cancer therapeutics

21 January 2018

1 reference

Application of a translational profiling approach for the comparative analysis of CNS cell types

21 January 2018

1 reference

A translational profiling approach for the molecular characterization of CNS cell types

21 January 2018

1 reference

Cell-type-specific isolation of ribosome-associated mRNA from complex tissues

21 January 2018

1 reference

Cancer immunotherapy--revisited

21 January 2018

1 reference

Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics

21 January 2018

1 reference

Randomized phase II trials: a long-term investment with promising returns

21 January 2018

1 reference

Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?

21 January 2018

1 reference

Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug?

21 January 2018

1 reference

Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis

21 January 2018

1 reference

Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.

21 January 2018

1 reference

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma

21 January 2018

1 reference

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

21 January 2018

1 reference

Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.

21 January 2018

1 reference

12 December 2020

Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium

1 reference

12 December 2020

Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas

1 reference

12 December 2020

Accrual to cancer clinical trials in the era of molecular medicine

1 reference

12 December 2020

Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved

1 reference

12 December 2020

Mechanisms of drug combinations: interaction and network perspectives

1 reference

12 December 2020

Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice

1 reference

12 December 2020

A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer.

1 reference

12 December 2020

Rethinking the metastatic cascade as a therapeutic target

1 reference

12 December 2020

Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models

1 reference

12 December 2020

Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models

1 reference

12 December 2020

The use of endostatin in the treatment of solid tumors

1 reference

12 December 2020

Fibroblast growth factors are required for efficient tumor angiogenesis

1 reference

12 December 2020

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

1 reference

12 December 2020

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NBT.2286

1 reference

PubMed ID

22781694

Dimensions Publication ID

27 August 2017

0 references

1 reference

PubMed ID

22781694